Form 4 holding
SVP, CHIEF LEGAL OFFICER
HALOZYME THERAPEUTICS, INC.
- Security class
- Common Stock
- Shares / value
- 49,929
- Estimated value
- $3,226,911
- Report date
- 12 Jun 2026
- Price
- $64.63
- Ownership
- Direct
Mark Howard Snyder - SVP, CHIEF LEGAL OFFICER at HALOZYME THERAPEUTICS, INC.
Issuer-level insider activity
- Role
- Svp, Chief Legal Officer
- Issuer ticker
- HALO on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
No buys or sells have been reported by Mark Howard Snyder since 28 Aug 2025
Reported holdings for Mark Howard Snyder in HALOZYME THERAPEUTICS, INC.
Form 4 holding
SVP, CHIEF LEGAL OFFICER
HALOZYME THERAPEUTICS, INC.
- Security class
- Restricted Stock Units
- Shares / value
- 10,068
- Estimated value
- $1,214,656
- Report date
- 12 Jun 2026
- Price
- $57.75
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
SVP, CHIEF LEGAL OFFICER
HALOZYME THERAPEUTICS, INC.
- Security class
- Option to Purchase Common Stock
- Shares / value
- 18,730
- Estimated value
- $313,504
- Report date
- 09 Feb 2026
- Price
- $13.87
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
SVP, CHIEF LEGAL OFFICER
HALOZYME THERAPEUTICS, INC.
- Security class
- Performance Stock Units
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 16 Feb 2026
- Price
- $58.29
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Mark Howard Snyder in HALOZYME THERAPEUTICS, INC.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.